Innate Pharma Total Assets
Innate Pharma total assets. Based on the latest financial reports, Innate Pharma (IPHA) holds total assets worth $62.69 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Innate Pharma for the company's overall valuation and market capitalisation.
Total Assets of Innate Pharma (2005–2025)
Total assets of Innate Pharma from 2005 to 2025. This chart illustrates how Innate Pharma's total assets have evolved over time, based on quarterly financial data. See latest Innate Pharma stock price today for real-time trading data and today's change.
Innate Pharma - Asset Composition Analysis
Innate Pharma Total Assets Breakdown (December 2025)
Innate Pharma total assets breakdown as of December 2025. Innate Pharma's total assets of $62.69 Million consist of 74.5% current assets and 25.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.8% |
| Accounts Receivable | $12.39 Million | 19.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Innate Pharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Innate Pharma's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Innate Pharma's current assets represent 74.5% of total assets in 2025, a decrease from 85.6% in 2005.
- Cash Position: Cash and equivalents constituted 44.8% of total assets in 2025, up from 10.4% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 19.8% of total assets.
Innate Pharma Competitors by Total Assets
Key competitors of Innate Pharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Innate Pharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.27 | 2.60 | 3.71 |
| Quick Ratio | 1.27 | 2.60 | 3.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.06 Million | $52.76 Million | $126.64 Million |
Innate Pharma - Advanced Valuation Insights
This section examines the relationship between Innate Pharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.10 |
| Latest Market Cap to Assets Ratio | 1.99 |
| Asset Growth Rate (YoY) | -43.6% |
| Total Assets | $62.69 Million |
| Market Capitalization | $124.79 Million USD |
Valuation Analysis
Above Book Valuation: The market values Innate Pharma's assets above their book value (1.99x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Innate Pharma's assets decreased by 43.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Innate Pharma (2005–2025)
The table below shows the annual total assets of Innate Pharma from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $62.69 Million | -43.55% |
| 2024-12-31 | $111.06 Million | -36.61% |
| 2023-12-31 | $175.19 Million | -15.72% |
| 2022-12-31 | $207.86 Million | -22.29% |
| 2021-12-31 | $267.50 Million | -12.99% |
| 2020-12-31 | $307.42 Million | -23.40% |
| 2019-12-31 | $401.36 Million | -11.05% |
| 2018-12-31 | $451.22 Million | +76.93% |
| 2017-12-31 | $255.02 Million | -9.43% |
| 2016-12-31 | $281.58 Million | -7.97% |
| 2015-12-31 | $305.96 Million | +237.36% |
| 2014-12-31 | $90.69 Million | +62.29% |
| 2013-12-31 | $55.88 Million | +15.71% |
| 2012-12-31 | $48.30 Million | -19.65% |
| 2011-12-31 | $60.11 Million | +25.20% |
| 2010-12-31 | $48.01 Million | -25.24% |
| 2009-12-31 | $64.22 Million | +5.52% |
| 2008-12-31 | $60.86 Million | -3.63% |
| 2007-12-31 | $63.15 Million | -8.81% |
| 2006-12-31 | $69.25 Million | +179.63% |
| 2005-12-31 | $24.77 Million | -- |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated t… Read more